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death in adults with IgA nephropathy secondary
to Henoch-Schönlein purpura: a monocentric
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Background: We established earlier the absolute renal risk (ARR) of dialysis/death (D/D) in primary IgA nephropathy
(IgAN) which permitted accurate prospective prediction of final prognosis. This ARR was based on the potential
presence at initial diagnosis of three major, independent, and equipotent risk factors such as hypertension,
quantitative proteinuria ≥ 1 g per day, and severe pathological lesions appreciated by our local classification
scoring ≥ 8 (range 0–20). We studied the validity of this ARR concept in secondary IgAN to predict future outcome
and focused on Henoch-Schönlein purpura (HSP) nephritis.
Methods: Our cohort of adults IgAN concerned 1064 patients with 101 secondary IgAN and was focused on 74
HSP (59 men) with a mean age of 38.6 at initial diagnosis and a mean follow-up of 11.8 years. Three major risk
factors: hypertension, proteinuria ≥1 g/d, and severe pathological lesions appreciated by our global optical score ≥8
(GOS integrated all elementary histological lesions), were studied at biopsy-proven diagnosis and their presence
defined the ARR scoring: 0 for none present, 3 for all present, 1 or 2 for the presence of any 1 or 2 risk factors. The
primary end-point was composite with occurrence of dialysis or death before (D/D). We used classical statistics and
both time-dependent Cox regression and Kaplan-Meier survival curve methods.
Results: The cumulative rate of D/D at 10 and 20 years post-onset was respectively 0 and 14% for ARR = 0 (23
patients); 10 and 23% for ARR = 1 (N = 19); 27 and 33% for ARR = 2 (N = 24); and 81 and 100% (before 20 y) in the 8
patients with ARR = 3 (P = 0.0007). Prediction at time of diagnosis (time zero) of 10y cumulative rate of D/D event was
0% for ARR = 0, 10% for ARR = 1, 33% for ARR = 2, and 100% by 8.5y for ARR = 3 (P = 0.0003) in this adequately treated
cohort.
Conclusion: This study clearly validates the Absolute Renal Risk of Dialysis/Death concept in a new cohort of
HSP-IgAN with utility to individual management and in future clinical trials.
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In IgA nephropathy (IgAN), one difficulty is to predict
accurately at time of diagnosis (by renal biopsy) the
ultimate prognosis one or two decades later of the
individual patient with the probability risk of reaching
end-stage renal failure with the need for dialysis or to die
before this event.
In primary IgAN, many risk factors predictive of
progression have been described [1,2] and in a previous
work [3], we focused on the following three consensual
and major risk factors: occurrence of arterial hypertension
(HT), amount of daily proteinuria, and severe renal lesions
on optical microscopy (appreciated by local pathological
scoring [4,5] or by the new Oxford classification [6]).
These risk factors were simplified and dichotomized,
before integration in an Absolute Renal Risk (ARR) score,
which proved to be an overall accurate predictor of ultimate
prognosis. These simplified risk factors, present or not
at time of diagnosis, were:-HT (Yes or No); daily pro-
teinuria ≥ 1 g/day (Yes or No);-and a global optical
score, GOS ≥ 8 (Yes or No). We have previously defined
the ARR score as the number of these risk factors present
at diagnosis with four possibilities: 0, 1, 2, and 3. This
ARR permitted us in a prospective study [3], including
332 patients with primary IgAN, to predict the cumulative
incidence rate at 20 years post clinical onset of the
combined final event, dialysis or death: 4% for ARR = 0;
9% for ARR = 1; 18% for ARR = 2; and 64% for ARR = 3.
These findings were also validated in a retrospective
historical cohort including 250 patients [3].
IgA nephropathies, defined as at least 1+ mesangial
IgA deposits by immunofluorescence, are clinically divided
in two groups:-primary IgAN, also called Berger’s disease
which represent 90% of the cases, and-secondary IgAN ob-
served in different clinical conditions: Henoch-Schönlein
Purpura, HSP, alcoholic liver cirrhosis, some cases of
Systemic Lupus Erythematosus, SLE, and few other rare
conditions.
The goal of this retrospective observational study was
to review all our cases of secondary IgAN and to apply
our ARR score for an additional validation in another
group of patients, and we focused on IGAN 2ary to HSP,
which represented the majority of the cases.
Methods
The patients
We have reviewed all our adult cases of secondary IgAN
collected from 1975 to 2010 and included with the
following criteria: to have a renal biopsy showing at
least 1+ mesangial IgA deposits and a minimum of 6
glomeruli available for optical microscopy (HSP clinical
nephritis without biopsy were excluded), and a clinical clas-
sification among the following conditions: HSP with clinical
purpura; overt clinical/pathological cirrhosis; systemiclupus erythematosus SLE; ankylosing spondylarthritis, AS;
and few others. Finally during this period, we have
registered 963 cases of primary IgAN and 101 second-
ary IgAN (9.5%, 101 over 1064). The aetiology of the
secondary cases were: HSP in 74 (73.3%); liver cirrhosis
in 19, SLE in 3, AS in 2, Goujerot-Sjögren syndrome in
1, systemic vasculitis in 1, and superimposed on a dia-
betic glomerulosclerosis in 1.
In this study, we report only on the 74 cases of IgAN
secondary to HSP: 59 men (80%) and 15 women with
at diagnosis a mean age of 38.6 (SD = 19.7) years and a
median age of 37.1 (extremes: 5.9 to 74.6) years. All patients
gave informed consent for the anonymous use of their
personal health data.
It should be noted that this cohort was adequately
treated with some heterogeneity to target these risk factors.
Overall, 46% (34/74) of the patients received a treatment
(over 6 months) with ACE inhibitors or ARBs for HT and/
or heavy proteinuria; 63% of all patients who developed
HT and 58% of patients with proteinuria ≥ 1 g/d received
this treatment; the % of patients treated by ARR category
(0, 1, 2, 3) was respectively 22, 47, 67, and 50. For steroid
treatment, overall 44 patients were treated (59%) and the %
by ARR category (0, 1, 2, 3) was respectively 35, 58, 75, and
88; the indication was severe pathological lesions (77%,
23/30) and/or heavy proteinuria at any time (81%, 29/36).
The number of patients receiving additional therapy was
6, 3, and 6 respectively for immunosuppressive agents
(4 Azathioprine, 1 Chlorambucil, and 1 Mabthera), plasma
exchanges (mean of 6 sessions), and tonsillectomy.
The methods
This is a retrospective monocentric study concerning an
observational cohort of patients. Our hospital institutional
review board (Comite de Protection des Personnes-Sud-Est
1) gave specific approval for this study.
Each patient chart was thoroughly reviewed with collec-
tion of clinical, biological, and pathological data at onset,
at diagnosis and at last follow-up.
The risk factors studied were:-hypertension defined as
blood pressure over 140/90 mmHg at different occasions
or already treated with antihypertensive agents including
diuretics;-daily proteinuria with a cut-off value of ≥1 g/day;
and-global optical score, GOS, integrating all elementary
lesions (glomerular index: 0 to 6, vascular index: 0 to 5,
tubular index: 0 to 4 and interstitial index: 0 to 5); the
cut-off value of ≥8 was previously extracted from ROC
curve with dialysis as the final event.
We focused mainly on these risk factors: HT present
or not at onset, at diagnosis, and at last follow-up. Blood
pressure was regularly recorded with the antihypertensive
treatment details; this variable was used only as dichotom-
ous: present or absent. Daily proteinuria at diagnosis
and at last follow-up with classification according to
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and ≥3 g/d; this variable was used both as continuous
or dichotomous: <1 g/d or ≥1 g/d. The diagnostic renal
biopsy was scored according to our local classification
already described [4,5] with calculation of GOS value
(scale from 0 to 20); this covariate was used both as con-
tinuous and dichotomous: <8 or ≥8 units. It is important
to mention that 52 patients had no crescents (<5%), 14
with a low % of crescents (5 to 24%), and 8 with a high %
of crescents (≥25%). Only one patient fulfilled the
definition of rapidly progressive glomerulonephritis with
more than 50% of crescents.
Time zero corresponded to disease onset with first renal
signs: usually gross haematuria, microscopic haematuria,
and/or proteinuria. For the calculation at time of diagnosis
of the future risk of D/D 10 years later, time zero was set
at time of the diagnostic biopsy.
The final combined primary event was the need for
dialysis with an eGFR < 15 ml/mn/1.73 m2 S (stage 5D) or
death occurring before. Reduction in GFR is a continuum
from stage 1 to stage 5 with a cut-off value of <60 ml/mn/
1.73 m2 which defined the start of chronic renal failure
(CRF or CKD-stage 3 and up) and was used as a second-
ary event.
The absolute renal risk (ARR) at diagnosis was simply
calculated by the number of risk factors present in each
individual patient with 4 possibilities: 0 for none of these
risk factors present, 3 for all these 3 risk factors present,
and 1 or 2 for 1 or 2 any risk factors present among the
3 preselected.
The statistics
We have used basic statistics with number and % for
qualitative variables and mean (+/− SD) for continuous
variables. Comparisons were done accordingly with
contingency tables or unpaired T or U tests.
We used Cox regression models for survival without the
event (dialysis/death) with both univariate or multivariate
analyses (with different covariates: categorical or dichot-
omous or continuous). The survival curves were built
according to the Kaplan-Meier method which accepts
only categorical variables, and the curves were compared
by the Logrank test. We have also done these statistics
with dialysis alone as end-point. All tests were done with
Statview 5 or SPSS 19 softwares.
Results
Baseline data at diagnosis
All 74 patients presented with cutaneous purpura at
least on one occasion with the classical characteristics;
the initial presentation was associated with arthralgia in
57 (77.0%) together with abdominal pain in 33 (44.6%)
leading to the diagnosis of Henoch-Schönlein purpura.
Renal involvement occurred at the same time of purpuraor within few weeks: microscopic haematuria was detected
at time of biopsy in all patients but one, and gross
haematuria was symptomatic in 29 (39.2%); significant
proteinuria ≥0.30 g/d was detected in 54 patients (73.0%).
The risks factors already present at time of biopsy
(diagnosis) are detailed in Table 1: 32 with proteinuria ≥1
g/d (43.2%); 29 with hypertension (39.2%); and 30 with
severe renal lesions with GOS ≥8 (40.5%). Progression
of the disease was demonstrated by both the number of
patients developing HT during the disease course: 22 at
disease onset (29.7%); 29 at time of diagnosis (39.2%),
and 49 at last FU or at final event (66.2%), and the number
of patients with CRF (CKD-3+) already at diagnosis 23%
(17/74) and at last follow-up 36.5% (27/74), and the number
of patients reaching the primary end-point (D/D): 2.7% at
diagnosis (2/74), and 25.7% at last FU (19/74 with 15 on
dialysis and 4 dying before dialysis). The mean overall
exposure time to the final risk was 11.8 (SD = 10.6) years
with 75% followed more than16.2 years.
The distribution of ARR score is given in Table 2 and
showed a significant difference according to age at diagno-
sis: more patients with score [0 + 1] in younger patients
(<25y) contrasting to more patients with score [2 + 3] in
older patients (>50y).
The % of patients with HT according to ARR 0, 1, 2, or
3, was at diagnosis 0, 37, 58 and 100 contrasting at last
follow-up with 30, 63, 92, and 100 respectively The % of
patients with proteinuria ≥1 g/d was at diagnosis 0, 37, 71,
and 100 and at any time 4, 47, 75, and 100 respectively
for ARR 0, 1, 2, and 3. The % of patients with GOS ≥8 at
diagnosis was respectively 0, 26, 71, and 100 for ARR 0, 1,
2, and 3.
Association of ARR score at diagnosis with progression to
final event
Overall, 15 patients reached ESRF and needed dialysis and
4 patients died before dialysis. These deaths concerned 3
men and 1 woman; causes were cardiovascular in 2,
infection in 1 and other in 1; these patients died at age
49, 66, 77 and 85 years.
The overall cumulative incidence rate of dialysis/death
event (Table 3) was respectively at 0, 5, 10, 15, and 20
years post-onset, 0% (74 at risk), 9% (50 at risk), 19%
(37 at risk), 25% (20 at risk), and 29% (15 at risk). By
Cox regression analysis, the ARR score at diagnosis
predicted nicely survival without D/D (X2 = 12.1; P = 0.007):
the relative risk with 95% confidence interval was RR =0.04
(0.005-0.35) for ARR = 0; RR = 0.13 (0.03-0.68) for ARR = 1;
and RR = 0.29 (0.09-0.96) for ARR = 2 as compared to
RR = 1 for ARR = 3. Similar data was obtained for pre-
diction of dialysis alone: X2 = 13.4; P = 0.004; RR = 0.04
(0.01-0.34) for ARR = 0, RR = 0.07 (0.01-0.61) for ARR = 1,
RR = 0.28 (0.09-0.88) for ARR = 2 as compared to 1 for
ARR = 3 (see Additional file 1: Table S1).
Table 1 Characteristics of the HSP-IgAN patients at diagnosis and at last follow-up
Items Units At diagnosis At last follow-up Test; P value
Age: mean (SD) years 38.6 (19.7) 46.8 (18.7)
Time interval: m(SD) years 3.6 (8.1) 8.2 (7.2)
Gross Haematuria: N (%) 29 (39.2%) 29 (39.2%)
Proteinuria:
Mean (SD): g/d 1.29 (1.56) 0.43 (0.68) T = −4.8; <0.0001
Median (extremes): g/d 0.80 (0.00-10.00) 0.18 (0.00-3.66)
Class (g/d):
<0.30 or absent N (%) 20 (27.0%) 44 (59.5%)
0.30–0.99 N (%) 22 (29.7%) 21 (28.4%) X2 = 15.0; NS (0.09)
1.00–2.99 N (%) 19 (25.7%) 7 (9.5%)
≥ 3.00 N (%) 13 (17.6%) 2 (2.7%)
Proteinuria ≥1 g/d N (%) 32 (43.2%) 9 (12.2%)
Hypertension: yes N (%) 29 (39.2%) 49 (66.2%) X2 = 24.3; <0.0001
SBP in HT + ve: m (SD) mm Hg 140.2 (16.9) 139.5 (17.2)
SBP in HT-ve: m (SD) mm Hg 128.4 (19.0) 120.2 (15.7)
DBP in HT + ve: m (SD) mm Hg 84.8 (13.5) 82.9 (9.2)
DBP in HT-ve: m (SD) mm Hg 75.8 (12.5) 76.6 (10.0)
Pathology/GOS (0–20):
Mean (SD) units 7.17 (2.75) /
Median (range) units 7.00 (2–16) /
GOS ≥ 8 N (%) 30 (40.5%) /
GVTI indices: m (SD) G = 3.38 (1.40) V = 1.95 (1.06) T = 0.87 (0.68) I = 0.97 (0.74)
End-point/eGFR:
Mean (SD) ml/mn/1.73 m2 S 82.2 (34.0) 60.0 (35.2) T = 6.3;<0.0001
Median (extremes) ml/mn/1.73 m2 S 85.3 (7.1-200.4) 68.7 (5.8-147.0)
eGFR staging:
Stage 1: ≥ 90 N (%) 30 (40.5%) 14 (18.9%)
Stage 2: 60–89 N (%) 27 (36.5%) 33 (44.6%)
Stage 3: 30–59 N (%) 11 (14.9%) 9 (12.2%) X2 = 60.3; <0.0001
Stage 4: 15–29 N (%) 3 (4.1%) 2 (2.7%)
Stage 5: <15 N (%) 3 (4.1%) 16 (21.6%)
CKD-3+ (eGFR < 60) N (%) 17 (23.0%) 27 (36.5%) X2 = 25.5; <0.0001
Dialysis N (%) 2 (2.7%) 15 (20.3%)
Death N (%) 0 (0.0%) 4 (5.4%)
Dialysis/Death N (%) 2 (2.7%) 19 (25.7%) X2 = 6.0; =0.01
Most important parameters are bolded.
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D/D (Figure 1) were nicely stratified from ARR = 0 (best
survival) to ARR = 3 (worse survival) and significantly
different by the Logrank test (X2 = 18.5; P = 0.0003). The
cumulative incidence rate of D/D event at 10 and 20 y
post-onset, were respectively 0% and 14% for ARR = 0;
10% and 23% for ARR = 1; 27% and 33% for ARR = 2;
and finally 81% at 10y for ARR = 3.Capacity of predicting ultimate progression by ARR
scoring at diagnosis
To achieve this goal, we set up time zero at time of diag-
nosis (renal biopsy) and recalculate both Cox regression
and Kaplan-Meier survival.
By Cox analysis, the ARR score predicted progression to
D/D (X2 = 21.0; P = 0.0001); the respective RR was 0.02
(CI: 0.002-0.14; P = 0.002) for ARR = 0, 0.06 (CI: 0.01-0.28;











Age at diagnosis: D/D event
N (%)(<25) (25–50) (>50)
0 0 (very low) 23 (31.1%) 18 (30.5%) 5 (33.3%) 15 6 2 1 (4.3%)
1 1 (low) 19 (25.7%) 13 (22.0%) 6 (40.0%) 2 9 8 3 (15.8%)
2 2 (high) 24 (32.4%) 20 (33.9%) 4 (29.3%) 4 8 12 9 (37.5%)
3 3 (very high) 8 (10.8%) 8 (13.6%) 0 (0.0%) 3 3 2 6 (75.0%)
X2 = 3.76 P = NS X2 = 20.7; P = 0.002
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for ARR = 2, and all as compared to 1 for ARR = 3.
By Kaplan-Meier method, the survival curves without
D/D (Figure 2) were also nicely stratified and significantly
different by the Logrank test (X2 = 37.6; P < 0.0001). The
cumulative incidence rate of D/D event at 10 years post-
diagnosis was respectively 0% for ARR = 0 (12 at risk),
10% for ARR = 1 (8 at risk), 33% for ARR = 2 (10 at risk),
and 100% reached D/D by 8.5 years for ARR = 3.
Similar data was obtained for prediction of Dialysis alone
by Logrank test (X2 = 44.30; P < 0.0001) with cumulative
incidence rate of dialysis at 10 y of 0% for ARR = 0, 10%
for ARR = 1, 25% for ARR = 2, and 100% reached dialysis
by 7 years.
Discussion
The strict application of our ARR score to a moderate-size
cohort of adult IgAN secondary to HSP demonstrated that
the ARR score was able to predict at time of evaluation
(diagnosis) the ultimate prognosis 10 and 20 years post-
onset with a good stratification from ARR = 0 to ARR = 3.
In this regard, our ARR scoring developed originally in a
large prospective cohort of primary IgAN [3] (N = 332)
was validated in this external cohort (but from the same
group) after being validated in an internal retrospectiveTable 3 Cumulative incidence rate of dialysis/death (D/D) in H
D/D Cumulative incidence rate Time = 0 %
(at risk)
Time = 5 y %
(at risk)
After Disease Onset:
Overall 0% (74) 9% (50)
ARR = 0 0% (23) 0% (18)
ARR = 1 0% (19) 0% (13)
ARR = 2 0% (24) 15% (15)
ARR = 3 0% (8) 42% (4)
After Diagnosis:
Overall 0% (74) 13% (42)
ARR = 0 0% (23) 0% (15)
ARR = 1 0% (19) 0% (11)
ARR = 2 0% (24) 14% (14)
ARR = 3 0% (8) 71% (2)
Most important parameters are bolded.cohort of 250 cases of primary IgAN. Recently a Norvegian
group confirmed the validity of our Absolute Renal Risk
in 633 primary IgAN patients and can serve as an external
validation of our predictive model (Knoop T, Vikse BE,
Svarstad E et al.; unpublished data).
The present study has some limitations:-the relative
small size population should be balanced by the fact
that HSP-nephritis represents at most 10% of all IgA
nephropathies;-it is clearly a retrospective study but
with prospective and homogenous collection of data in
the patients chart similar to our prospective cohort of
primary IgAN;-and this monocentric study warrants
more homogeneity in the diagnosis and management of
the patients than a multicentric study, which however will
have permitted to include more patients.
The question of including a marker of renal function
in our model was already discussed in our original paper
[3]:-we thought that it was not appropriate to use the
same item such as GFR both as risk factor and as primary
end-point (dialysis with GFR in stage V);-nevertheless,
eGFR staging (1 to 5) at diagnosis was tested but
substituted to HT and proteinuria ≥1 g/d in the sub-
group of patients with already chronic renal failure,
CRF (eGFR < 60 ml/mn/1.73). In this small cohort, we
found no significant impact of CRF tested as additionalSP-IgAN patients
Time = 10 y %
(at risk)
Time =15 y %
(at risk)
Time = +20 y %
(at risk)
19% (37) 25% (20) 29% (15)
0% (16) 0 % (9) 14% (6)
10% (8) 23% (2) /
27% (12) 33% (8) 33% (6)
81% (1) at 8.5y / /
25% (30) 40% (9) /
0% (12) 0% (5) /
10% (8) 25% (2) /
33% (10) 61% (2) /
100% (2) at 8.5y / /
Figure 1 Kaplan-Meier survival curves without Dialysis/Death
event and according to Absolute Renal Risk score at Diagnosis
in HSP-IgAN patients (time zero is disease onset).
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(0 to 3) or with the 3 covariates (HT, proteinuria ≥ 1 g/d,
and GOS ≥ 8); see Additional file 1: Table S1.
It is remarkable to notice the similarities between this
HSP cohort and our prospective cohort of primary IgA
nephropathy, IGAN-STET-CO: -The distribution of the
three major risk factors was very similar: respectively for
HSP and IGAN-STET-CO, 39% versus 36% for HT
present at diagnosis; 43% versus 30% for proteinuria ≥ 1
g/d at diagnosis; and 40% versus 36% for GOS ≥8 (the
mean GOS values were also very closed: 7.17 versus
7.00); -The values of eGFR at diagnosis and at last FU
were also very closed with similar staging distribution:
23% versus 26% of patients in CKD-3+; but finally at last
follow-up, we have observed D/D events in 26% of HSP-
IgAN patients versus 14% in primary IgAN patients; -In
the Cox analyses," the respective weight of each risk factor
was difficult to appreciate totally in this paper because ofFigure 2 Prospective Kaplan-Meier survival curves without
Dialysis/Death (D/D) event and according to Absolute Renal
Risk score at Diagnosis in HSP-IgAN patients (time zero is
biopsy-proven diagnosis).the limited number of patients in this HSP cohort; the
β/SE ratios for each dichotomous factor was in the
following order: greater for the absence of GOS ≥ 8,
then absence of proteinuria ≥1 g/d and last absence of HT.
From the difference in the number of final D/D events
between HSP-IgAN and primary IgAN, we could not
derived any conclusion because one cohort was retro-
spective and the other prospective; in addition, patients
with HSP-IgAN received less and later therapy with
ACEI or ARBs which could have decreased survival
without D/D.
Many clinical studies concerning HSP nephritis in adults
have been published [7-11]; few focused on long-term
prognosis with characterization of risk factors [12-16];
and others on comparisons between adults and children
[17-21]. The long-term prognosis of HSP nephritis was
found worse in adults than in children/adolescent. The
main clinical risk factors were also proteinuria over 1 g/d
and hypertension. Just recently, an observational study
[22] demonstrated that the final prognosis in adults
was similar in HSP-IgAN and in primary IgAN, when
fully matched by propensity score method (but HT was
included as a comorbid condition in the matching and
not as an individual risk factor for progression).
Concerning renal pathology, the most predictive optical
glomerular lesions for end-stage renal failure were the
presence of crescents and endocapillary hypercellularity.
To our knowledge, there has been no specific use of
Oxford classification in SHP-IgAN for potential validation,
but a recent study in primary IgA nephropathy confirmed
that the % of crescents was a poor prognosis marker and
should be included in the revised Oxford classification
[23] for primary IgAN. We have new information [24]
(plus Berthoux F et al., unpublished data) in a subgroup
of 151 patients with primary IgAN concerning the equiva-
lence between our Local classification (GOS) and the
International/Oxford classification (MEST):-the linear
correlation is excellent (R = 0.79; P < 0.0001) with the
formula “MEST = (+0.256*GOS)-0.725 “;-the respective
range is 0 to 20 for GOS and 0 to 5 for MEST;-MEST ≥2
correspond to GOS ≥8;-and the respective power of
MEST and GOS in predicting dialysis is similar in
multivariate Cox and multivariate logistic regressions
analyses with continuous or dichotomous covariates.
It should be mentioned that the % of crescents was
integrated in the glomerular index of our local classifica-
tion with final higher GOS values. By monovariate Cox
regression for prediction of dialysis alone, the variable “%
of crescents” had a significant effect (p > 0.0001).
The similarities between primary IgAN and HSP-IgAN
have been stressed since a long time, but recently the
common pathogenesis was demonstrated [25,26] with
data on the autoantigen, galactose-deficient IgA1, and
specific autoantibodies (IgG and IgA subclasses); a
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IgA1 was also described [27].
It is out of our scope to review the treatment of HSP-
IgAN [28] but obviously the treatment should target the
risk factors when present: adequate control of hypertension
with blood pressure below 130/80; reduction of proteinuria
with ACE inhibitors and ARB’s; steroid treatment for severe
renal lesions eventually associated to immunosuppressive
agents.
In our study, the use of ACEI and/or ARBs was limited:
overall respectively 63% and 58% of all patients with HT
at anytime (31/49) and proteinuria ≥1 g/d at anytime
(21/36) received such treatment; however in the subgroup
of patients diagnosed since 1990 (N = 49), this % rose
to 74 and 68% respectively. Nevertheless, survival
without dialysis/death was strictly similar in the two
subgroups: <1990 versus ≥1990.
Conclusion
In a retrospective cohort of 74 adult patients with IgA
nephropathy secondary to Henoch-Schönlein Purpura,
we have validated the Absolute Renal Risk concept in
the prediction at time of diagnosis of future outcome
(dialysis/death or dialysis alone).
Additional file
Additional file 1: Table S1. Cox regression analyses for prediction of
Dialysis alone.
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